BioWorld and Medical Device Daily joined the Life Sciences business of Thomson Reuters this past July. Since that time, the look and feel of BioWorld and Medical Device Daily products and materials gradually have been evolving to align with Thomson Reuters. You see the most significant change in today’s issue of BioWorld Today. Read More
Celldex Therapeutics Inc.’s public offering of 7 million shares at $24.50 each brings net proceeds of about $162.7 million, which should get the Hampton, N.J.-based firm “comfortably through 2016,” said CEO Anthony Marucci. “We came into the [financing] with $136.6 million already on the balance sheet,” he noted. Read More
As researchers and clinicians converge on New Orleans for the annual meeting of the American Society of Hematology (ASH) this weekend, one thing is clear: There will be a bumper crop of data on drugs for the treatment of chronic lymphocytic leukemia (CLL). The society itself is putting on a press briefing on “the changing landscape of CLL.” Read More
Receptos Inc. moved one step closer to its goal of setting a safer standard in oral therapy for multiple sclerosis (MS), reporting positive data from a planned interim analysis of the Phase II portion of RADIANCE, the company’s Phase II/III trial of RPC1063 in relapsing MS. (See BioWorld Insight, Nov. 4, 2013.) Read More
Auxilium Pharmaceuticals Inc., of Chesterbrook, Pa., said the U.S. District Court for the District of Delaware granted a motion from Upsher-Smith Laboratories Inc., of Maple Grove, Minn., for a summary judgment with respect to its attempts to bring a testosterone gel product to market via the 505(b)(2) pathway using Auxilium’s Testim product as its reference drug. Read More
Biogen Idec Inc., of Weston, Mass., and Swedish Orphan Biovitrum AB, of Stockholm, Sweden, disclosed positive results from A-LONG, a Phase III trial that evaluated a long-lasting clotting factor candidate in people with hemophilia A. Read More
Druggability Technologies (DRGT), of Dublin, said it entered a multiyear collaboration with Bayer HealthCare, of Leverkusen, Germany, to deploy DRGT’s Super-API platform in support of Bayer’s formulation efforts directed at improving compound solubility and bioavailability. Read More
Eli Lilly and Co., of Indianapolis, reported that three Phase III studies of edivoxetine failed to meet the primary objective of superior efficacy in major depressive disorder (MDD) after eight weeks of treatment. When added to a selective serotonin reuptake inhibitor, edivoxetine did not separate from placebo on the Montgomery-Asberg Depression Rating Scale in the acute, randomized, placebo-controlled studies (LNBM, LNBQ and LNBR). Read More
